In the last trading session, 9.35 million Bristol-Myers Squibb Co (NYSE:BMY) shares changed hands as the company’s beta touched 0.39. With the company’s per share price at $49.97 changed hands at $0.97 or 1.98% during last session, the market valuation stood at $101.69B. BMY’s last price was a discount, traded about -26.74% off its 52-week high of $63.33. The share price had its 52-week low at $39.35, which suggests the last value was 21.25% up since then.
Analysts gave the Bristol-Myers Squibb Co (BMY) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.64. If we narrow down to specifics, the data shows that 0 out of 14 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 9 recommended BMY as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Bristol-Myers Squibb Co’s EPS for the current quarter is expected to be 1.64.
Bristol-Myers Squibb Co (NYSE:BMY) trade information
Instantly BMY was in green as seen at the end of in last trading. With action 3.91%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -11.65%, with the 5-day performance at 3.91% in the green. However, in the 30-day time frame, Bristol-Myers Squibb Co (NYSE:BMY) is 7.58% up.
The consensus price target for the stock as assigned by Wall Street analysts is 66.5, meaning bulls need an upside of 24.86% from its current market value. According to analyst projections, BMY’s forecast low is 65 with 68 as the target high. To hit the forecast high, the stock’s price needs a -36.08% plunge from its current level, while the stock would need to soar -30.08% for it to hit the projected low.
Bristol-Myers Squibb Co (BMY) estimates and forecasts
Year-over-year growth is forecast to reach -4.42% down from the last financial year.
Consensus estimates given by 17 financial analysts project the company’s revenue in the current quarter to hit an average of 11.32B. 16 analysts are of the opinion that Bristol-Myers Squibb Co’s revenue for the current quarter will be 11.64B. The company’s revenue for the corresponding quarters a year ago was 12.2B and 11.89B respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -7.24%. The estimates for the next quarter sales put growth at -2.12%. The 2025 estimates are for Bristol-Myers Squibb Co earnings to increase by 492.90%, but the outlook for the next 5-year period is at 72.94% per year.
BMY Dividends
Bristol-Myers Squibb Co is expected to release its next quarterly earnings report in July. The 4.88% annual yield figure for the share gives it an annual dividend of 2.44. It is important to note, however, that the 4.88% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.
Bristol-Myers Squibb Co (NYSE:BMY)’s Major holders
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 7.8273% or 158.66 million shares worth $6.59 billion as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund. With 64.1 shares estimated at $3.2 billion under it, the former controlled 3.15% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard 500 Index Fund held about 2.77% of the shares, roughly 56.39 shares worth around $2.82 billion.
